These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25124221)

  • 1. Site-directed delivery of nitric oxide to cancers.
    Sharma K; Chakrapani H
    Nitric Oxide; 2014 Dec; 43():8-16. PubMed ID: 25124221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroreductase-activated nitric oxide (NO) prodrugs.
    Sharma K; Sengupta K; Chakrapani H
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of novel nitroreductase enzyme-activated nitric oxide prodrugs to site-specifically kill bacteria.
    Hibbard HAJ; Reynolds MM
    Bioorg Chem; 2019 Dec; 93():103318. PubMed ID: 31586703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide-donating materials and their potential in pharmacological applications for site-specific nitric oxide delivery.
    Eroy-Reveles AA; Mascharak PK
    Future Med Chem; 2009 Nov; 1(8):1497-507. PubMed ID: 21426062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy.
    Gwenin VV; Gwenin CD; Kalaji M
    Langmuir; 2011 Dec; 27(23):14300-7. PubMed ID: 22014024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph-Directed Self-Immolative Nitric Oxide Prodrug for Inhibition of Intractable Metastatic Cancer.
    Kim T; Suh J; Kim J; Kim WJ
    Adv Sci (Weinh); 2022 Mar; 9(8):2101935. PubMed ID: 35317221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver.
    Saavedra JE; Billiar TR; Williams DL; Kim YM; Watkins SC; Keefer LK
    J Med Chem; 1997 Jun; 40(13):1947-54. PubMed ID: 9207935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INDQ/NO, a bioreductively activated nitric oxide prodrug.
    Sharma K; Iyer A; Sengupta K; Chakrapani H
    Org Lett; 2013 Jun; 15(11):2636-9. PubMed ID: 23659457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
    Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide--a novel therapeutic for cancer.
    Coulter JA; McCarthy HO; Xiang J; Roedl W; Wagner E; Robson T; Hirst DG
    Nitric Oxide; 2008 Sep; 19(2):192-8. PubMed ID: 18485922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme Mimics for the Catalytic Generation of Nitric Oxide from Endogenous Prodrugs.
    Yang T; Zelikin AN; Chandrawati R
    Small; 2020 Jul; 16(27):e1907635. PubMed ID: 32372556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of nitric oxide via a 'bump-and-hole'-based enzyme-prodrug pair.
    Hou J; Pan Y; Zhu D; Fan Y; Feng G; Wei Y; Wang H; Qin K; Zhao T; Yang Q; Zhu Y; Che Y; Liu Y; Cheng J; Kong D; Wang PG; Shen J; Zhao Q
    Nat Chem Biol; 2019 Feb; 15(2):151-160. PubMed ID: 30598545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Light-triggered nitric oxide delivery to malignant sites and infection.
    Heilman B; Mascharak PK
    Philos Trans A Math Phys Eng Sci; 2013 Jul; 371(1995):20120368. PubMed ID: 23776301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular design of S-nitrosothiols as photodynamic agents for controlled nitric oxide release.
    Giles NM; Kumari S; Gang BP; Yuen CW; Billaud EM; Giles GI
    Chem Biol Drug Des; 2012 Sep; 80(3):471-8. PubMed ID: 22642531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Begent RH
    Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.